“…Data comparing pulmonary hypertension (especially "reversible") and mortality post-transplant remain controversial. 5,[12][13][14][15][16][17][18][19][20][21][22][23][24][25] There are many reasons for these varied findings. Differences in recipient age studied (some including pediatric patients), definition of pulmonary hypertension used, inclusion of data on whether reversibility was assessed or not (and, if so, the extent to which it reversed), whether or not the mortality data were risk-adjusted, short vs long-term outcome assessment, different statistical methods and approach to missing data applied, etc., are a few reasons why these studies have shown conflicting results.…”